Malvinder Mohan Singh, CEO and Managing Director, Ranbaxy said, "It is yet another first for Ranbaxy in the Japenese market and reflects our techno-commercial strengths and capabilities in the Japenese market. The present reform process by the government of Japan is encouraging generic substitution, and Ranbaxy is well positioned to offer its affordable generic alternatives to the Japenese healthcare system."
Earlier during the year Ranbaxy had received authroisation from the Ministry of Health and Labour Welfare (MHLW-Japan) for marketing the generic version of Amlodpine tablets 2.5 mg and 5 mg.
The results of the reform process by the government of Japan is reflected in the growing genericization of medicines, says the company. The generics market is expected to grow 30 per cent by volume by 2012. Ranbaxy already has a total of four products in the Japanese generics market. Since 2004, Ranbaxy has filed seven products in Japan and so far has 100 per cent success rate in getting approvals.